Peptide-based therapies are an emerging treatment strategy for diabetes, offering new ways to manage blood sugar levels and improve insulin sensitivity. These therapies include glucagon-like peptide-1 (GLP-1) receptor agonists, which stimulate insulin secretion in response to food intake and inhibit glucagon release, helping to lower blood glucose levels. Additionally, amylin analogs and other peptide-based hormones target various aspects of metabolism to enhance glycemic control. Such therapies are beneficial in type 2 diabetes and can improve weight management, reduce the risk of hypoglycemia, and offer better long-term outcomes when combined with other treatments.
Join the Diabetes 2027 delegation
Orlando · October 25–27, 2027· Hybrid · in-person & virtual
Attend without presenting.
